|
|
|
Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time.
Sign up now!
Already registered? Please sign in.
Alternatively, please use our pay-per-view service. |
|
|
 |
Industry Events |
 |
The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023)
12-13 June 2023, Hilton Geneva Hotel & Conference Centre, Geneva, Switzerland
The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023) gathers top-level management from pharmaceutical
companies of manufacturing, primary and secondary packaging, purchasing,
and supply chain and procurement sectors, CMOs and CDMOs leaders, heads
from government and institution on 12-13, June, 2023 in Geneva,
Switzerland.
More info >> |
|
 |
News and Press Releases |
 |
Prometheus’ PRA023 holds significant advantage over all therapies for Crohn’s Disease, says GlobalData
At the European Crohn´s and Colitis Organisation (ECCO), Prometheus
Bioscience presented results from its Phase 2a APOLLO-CD clinical trial
of PRA023 in Crohn’s Disease (CD). The presentation highlighted the
efficacy and safety of PRA023, an anti-TL1A asset, in the small sample
size (N=50) of CD patients. The area of particular interest from this
presentation was the reported findings of Prometheus’ proprietary
companion diagnostic test (CDx) being evaluated alongside PRA023. If
this asset is shown to be effective and advance to the market, the use
of the CDx with PRA023 gives the treatment and Prometheus a significant
advantage over all CD therapies currently in development and on the
market, according to GlobalData, a leading data and analytics company.
More info >> |
|
|
